Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 24 11:04AM ET
13.00
Dollar change
+0.40
Percentage change
3.17
%
Index- P/E- EPS (ttm)- Insider Own39.35% Shs Outstand54.07M Perf Week3.33%
Market Cap702.85M Forward P/E- EPS next Y- Insider Trans54.44% Shs Float32.79M Perf Month-
Income- PEG- EPS next Q- Inst Own19.69% Short Float0.00% Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.00 Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Short Interest0.00M Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range10.45 - 13.53 Perf YTD-2.26%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-3.93% Beta-
Dividend TTM- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low24.39% ATR (14)1.12
Dividend Ex-Date- Current Ratio- EPS Y/Y TTM- Oper. Margin- RSI (14)- Volatility8.43% -
Employees- Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price32.33
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q- Payout- Rel Volume0.13 Prev Close12.60
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume269.86K Price13.00
SMA206.56% SMA506.56% SMA2006.56% Trades Volume9,715 Change3.17%
Date Action Analyst Rating Change Price Target Change
Jul-23-24Initiated Morgan Stanley Overweight $36
Jul-23-24Initiated Leerink Partners Outperform $29
Jul-23-24Initiated Guggenheim Buy $32
Jul-23-24Initiated Cantor Fitzgerald Overweight
Jun-27-24 11:57PM
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Foresite Labs, LLC10% OwnerJul 01 '24Buy16.002,500,00040,000,0005,584,889Jul 03 09:31 PM
Foresite Capital Management V,10% OwnerJul 01 '24Buy16.002,500,00040,000,0005,584,889Jul 03 09:30 PM
Tananbaum James B.DirectorJul 01 '24Buy16.002,500,00040,000,0005,584,889Jul 03 09:30 PM